Scoop: J&J-backed Aro Biotherapeutics eyes nine-figure raise with first trial on horizon
Aro Biotherapeutics is en route to the clinic, and a nine-figure capital infusion is in view.
The Philadelphia biotech is “in the process of raising a Series B,” president and CEO Sue Dillon confirmed to Endpoints News via email in the last few days of 2022. An SEC filing from last week outlined a $100 million round that has so far attracted a dozen investors and about one-quarter of the company’s financing goal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.